CervoMed成功获得一项新的美国专利,该专利将其在研药物Neflamapimod用于治疗纯路易体痴呆患者的权益保护期延长至2042年。这项专利授权巩固了该公司在这一特定神经退行性疾病治疗领域的知识产权地位,为其核心资产的长期商业化前景提供了法律保障。
CervoMed成功获得一项新的美国专利,该专利将其在研药物Neflamapimod用于治疗纯路易体痴呆患者的权益保护期延长至2042年。这项专利授权巩固了该公司在这一特定神经退行性疾病治疗领域的知识产权地位,为其核心资产的长期商业化前景提供了法律保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.